Abstract
Congestive heart failure (CHF) is characterized not only by profound abnormalities in the haemodynamic profile but also by changes in sympathetic cardiovascular function. These neurogenic abnormalities are important features of the disease that can affect the prognosis of CHF and to become a target for therapeutic intervention. This article addresses 4 major issues. It will first examine the evidence that a hyperadrenergic state is a hallmark of CHF, based on data collected via indirect (plasma norepinephrine, power spectral analysis of the heart rate signal) and direct (microneurography, norepinephrine spillover, radioimaging techniques visualizing myocardial neural network) approaches. It will then provide an overview on the central, reflex and metabolic factors potentially responsible for the phenomenon. The review also analyses the clinical consequences of the adrenergic alteration, with particular emphasis on the effects of the sympathetic overdrive on disease progression, arrhythmogenic threshold, adverse clinical outcomes as well as sudden death. The final part of the review will examine the therapeutic implications of the above mentioned findings and discuss the effects of pharmacological and non- pharmacological interventions on the sympathetic abnormalities of the heart failure state.
Keywords: Heart failure, sympathetic nervous system, prognosis, baroreflex, drugs
Current Vascular Pharmacology
Title: Sympathetic Activation in Congestive Heart Failure: Evidence, Consequences and Therapeutic Implications
Volume: 7 Issue: 2
Author(s): Guido Grassi, Gino Seravalle, Fosca Quarti-Trevano and Raffaella Dell'Oro
Affiliation:
Keywords: Heart failure, sympathetic nervous system, prognosis, baroreflex, drugs
Abstract: Congestive heart failure (CHF) is characterized not only by profound abnormalities in the haemodynamic profile but also by changes in sympathetic cardiovascular function. These neurogenic abnormalities are important features of the disease that can affect the prognosis of CHF and to become a target for therapeutic intervention. This article addresses 4 major issues. It will first examine the evidence that a hyperadrenergic state is a hallmark of CHF, based on data collected via indirect (plasma norepinephrine, power spectral analysis of the heart rate signal) and direct (microneurography, norepinephrine spillover, radioimaging techniques visualizing myocardial neural network) approaches. It will then provide an overview on the central, reflex and metabolic factors potentially responsible for the phenomenon. The review also analyses the clinical consequences of the adrenergic alteration, with particular emphasis on the effects of the sympathetic overdrive on disease progression, arrhythmogenic threshold, adverse clinical outcomes as well as sudden death. The final part of the review will examine the therapeutic implications of the above mentioned findings and discuss the effects of pharmacological and non- pharmacological interventions on the sympathetic abnormalities of the heart failure state.
Export Options
About this article
Cite this article as:
Grassi Guido, Seravalle Gino, Quarti-Trevano Fosca and Dell'Oro Raffaella, Sympathetic Activation in Congestive Heart Failure: Evidence, Consequences and Therapeutic Implications, Current Vascular Pharmacology 2009; 7 (2) . https://dx.doi.org/10.2174/157016109787455699
DOI https://dx.doi.org/10.2174/157016109787455699 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Written Consent to Use the Drug in Children: The Problem of Off-Label Drugs
Current Pharmaceutical Design A Virtual Screening Approach for the Identification of High Affinity Small Molecules Targeting BCR-ABL1 Inhibitors for the Treatment of Chronic Myeloid Leukemia
Current Topics in Medicinal Chemistry The Adipose Tissue as a Source of Vasoactive Factors
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Hepatocyte Growth Factor (HGF), an Endogenous Pulmotrophic Regulator, for the Rescue of Acute and Chronic Lung Diseases
Current Signal Transduction Therapy The Effect of Resveratrol dose and Duration of Treatment on Blood Pressure in Patients with Cardiovascular Disorders: A Systematic Review
Current Drug Discovery Technologies Colorectal Cancer Microenvironment: Among Nutrition, Gut Microbiota, Inflammation and Epigenetics
Current Pharmaceutical Design Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis
Current Cancer Drug Targets Mechanisms And Prevention Of TAVI-Related Cerebrovascular Events
Current Pharmaceutical Design COX-2 Inhibitors Celecoxib and Parecoxib: Valuable Options for Postoperative Pain Management
Current Topics in Medicinal Chemistry Patent Annotations
Recent Patents on Biotechnology Metallothioneins and Platinum(II) Anti-Tumor Compounds
Current Medicinal Chemistry Targeted Therapies in Lung Cancer
Current Pharmaceutical Design Cardiovascular Effects of Green Tea Catechins: Progress and Promise
Recent Patents on Cardiovascular Drug Discovery Covid-19: An Update on Clinical Features, Diagnosis, and Treatment Strategies
Coronaviruses Activin and TGF-β Effects on Brain Development and Neural Stem Cells
CNS & Neurological Disorders - Drug Targets Pharmacogenetics of Antihypertensive Therapies: Can this be Applied in the Clinic?
Current Pharmacogenomics and Personalized Medicine GPCR Drug Discovery: Novel Ligands for CNS Receptors
Recent Patents on CNS Drug Discovery (Discontinued) Myocardial Energy Transport and Heart Failure
Current Cardiology Reviews Chronopharmacology and Antimicrobial Therapeutics
Current Clinical Pharmacology Oleic Acid in Olive Oil: From a Metabolic Framework Toward a Clinical Perspective
Current Pharmaceutical Design